Stockreport

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy [Yahoo! Finance]

Entrada Therapeutics, Inc.  (TRDA) 
PDF changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments – – ENTR-601-44 demonstrated significant plasma concentration, muscle concentrat [Read more]